Compass Therapeutics Files 8-K on Financial Condition & Operations

TL;DR

**CMPX just dropped an 8-K on financials, check it for new info.**

AI Summary

Compass Therapeutics, Inc. filed an 8-K on January 5, 2024, to report on its 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure.' This filing indicates that the company is providing an update on its financial status and operations, likely to ensure fair and broad dissemination of material non-public information. For investors, this matters because it signals that new financial information, potentially impacting the stock price, has been released, and they should review the full filing for details on the company's performance and outlook.

Why It Matters

This filing indicates that Compass Therapeutics is providing an update on its financial health and operational performance, which could influence investor sentiment and stock valuation.

Risk Assessment

Risk Level: medium — The filing itself is routine, but the underlying financial information it references could contain significant risks or opportunities for investors.

Analyst Insight

Investors should review the full content of the 8-K filing, which is not fully provided here, to understand the specific financial results and operational updates disclosed by Compass Therapeutics, Inc. This will help assess the company's current performance and future outlook.

Key Players & Entities

• Compass Therapeutics, Inc. (company) — the registrant filing the 8-K
• January 5, 2024 (date) — date of earliest event reported and filing date
• 001-39696 (other) — Commission File Number for Compass Therapeutics, Inc.
• CMPX (other) — trading symbol for Compass Therapeutics, Inc. Common Stock
• NASDAQ Capital Market (other) — exchange where Compass Therapeutics, Inc. Common Stock is registered

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share CMPX NASDAQ Capital
• $152 million — arketable securities were approximately $152 million as of December 31, 2023. This amount is

Filing Documents

• f8k_010524.htm (8-K) — 16KB
• exh_991.htm (EX-99.1) — 11KB
• 0001171843-24-000082.txt ( ) — 228KB
• gnw-20190101.xsd (EX-101.SCH) — 3KB
• gnw-20190101_def.xml (EX-101.DEF) — 25KB
• gnw-20190101_lab.xml (EX-101.LAB) — 33KB
• gnw-20190101_pre.xml (EX-101.PRE) — 22KB
• f8k_010524_htm.xml (XML) — 3KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. Compass Therapeutics, Inc. (the "Company") estimates that its cash, cash equivalents and marketable securities were approximately $152 million as of December 31, 2023. This amount is unaudited and preliminary and is subject to completion of financial closing procedures. As a result, this amount may differ materially from the amount that will be reflected in the Company's financial statements as of and for the year ended December 31, 2023. The information in this Item 2.02 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Forward-Looking Statements

Forward-Looking Statements The Company cautions readers that statements contained in this report regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company's current beliefs and expectations. Such forward-looking statements include the Company's estimated cash, cash equivalents and marketable securities as of December 31, 2023. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Such risks and uncertainties include, but are not limited to, potential changes in estimated cash and cash equivalents based on the completion of financial closing procedures and release of final 2023 results, and other risks described in the Company's filings with the SEC. The Company cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On January 5, 2024, the Company issued a press release announcing updated program timelines, additional clinical data, change in management and year-end cash position. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release issued on January 5, 2024 titled "Compass Therapeutics Provides Corporate Update" 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Compass Therapeutics, Inc. Date: January 5, 2024 By: /s/ Neil Lerner Neil Lerner VP Finance

View Full Filing

View this 8-K filing on SEC EDGAR